Literature DB >> 2724674

Preventive effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits.

M Kobayashi1, F Ishida, T Takahashi, K Taguchi, K Watanabe, I Ohmura, T Kamei.   

Abstract

MK-733 was found to prevent an increase of serum cholesterol levels in cholesterol-fed rabbits, and lovastatin also markedly inhibited their increase. MK-733 and lovastatin inhibited the increase of very low density lipoprotein (VLDL) and low density lipoprotein (LDL) cholesterol, and it slightly affected the high density lipoprotein (HDL) cholesterol levels. MK-733 and lovastatin suppressed the increase of serum phospholipid levels and slightly affected the triglyceride levels. MK-733 suppressed the development of atherosclerosis in coronary arteries and aorta, and lovastatin also diminished their development.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2724674     DOI: 10.1254/jjp.49.125

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  8 in total

1.  Effect of lovastatin on acyl-CoA: cholesterol O-acyltransferase (ACAT) activity and the basolateral-membrane secretion of newly synthesized lipids by CaCo-2 cells.

Authors:  N T Kam; E Albright; S Mathur; F J Field
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

Review 2.  Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

Authors:  J P Desager; Y Horsmans
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

Review 3.  Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.

Authors:  P Chrisp; N J Lewis; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

Review 4.  Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.

Authors:  G L Plosker; A J Wagstaff
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

5.  Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics.

Authors:  G Paolisso; S Sgambato; S De Riu; A Gambardella; M Verza; M Varricchio; F D'Onofrio
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 6.  Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 7.  Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.

Authors:  G L Plosker; D McTavish
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

8.  Metabolic fate of 2,2-dimethylbutyryl moiety of simvastatin in rats: identification of metabolites by gas chromatography/mass spectrometry.

Authors:  N Uchiyama; Y Kagami; Y Saito; S Abe; M Ohtawa; S Hata
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jul-Sep       Impact factor: 2.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.